TY - CHAP M1 - Book, Section TI - Sickle-Cell Disease A1 - Moryl, Natalie A2 - Bajwa, Zahid H. A2 - Wootton, R. Joshua A2 - Warfield, Carol A. Y1 - 2016 N1 - T2 - Principles and Practice of Pain Medicine, 3e AB - Sickle-cell disease (SCD) is the most prevalent single-gene disorder, affecting about 100,000 Americans. Sickle-cell disease is a debilitating condition associated with chronic anemia, stroke, splenic and renal dysfunction, susceptibility to bacterial infections in children, acute chest syndrome, and pain crises. Each year in the United States, an average of 75,000 hospitalizations are due to SCD, costing approximately $475 million. Despite a decrease in mortality in children with SCD over the last 25 years, median life expectancy for most SCD patients remains less than 50 years of age. Although tremendous resources have been invested in finding a cure, barriers to analgesia in SCD remain and stereotyping of patients persists. Major barriers to pain management are misconceptions regarding patients’ report of pain, use of opioids and other pain medications, and perception of addiction. This chapter discusses the correlation between SCD pain and mortality; mistrust between patients and health care providers (HCPs) as one reason for undertreated pain; patients’ perceptions of health care system response to their needs; and the need for clinical guidelines to provide appropriate comprehensive care to patients with SCD. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - neurology.mhmedical.com/content.aspx?aid=1131936155 ER -